Torricelli Federica, Lococo Filippo, Di Stefano Teresa Severina, Lorenzini Eugenia, Piana Simonetta, Valli Riccardo, Rena Ottavio, Veronesi Giulia, Billè Andrea, Ciarrocchi Alessia
Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
Cancers (Basel). 2020 Aug 29;12(9):2454. doi: 10.3390/cancers12092454.
Malignant Pleural Mesothelioma (MPM) is a heterogeneous disease. Morphologically, three different phenotypes are distinguishable: epithelioid (e-), sarcomatoid (s-) and biphasic (biph-) MPM, the latest, being a mixture of e- and s-MPM cells. Being an intermediate entity, management of biph-MPM, remains debatable and controversial, with different guidelines recommending distinct approaches. Identification of biph-MPM associated genetic alterations, through deep sequencing analysis, may provide useful tools to understand these lesions. A retrospective cohort of 69 surgically resected MPMs, 39 biph-MPMs (56.5%) and 30 e-MPMs (43.5%) was selected. A separate set of 16 biph-MPM was used as validation set. Deep sequencing analysis on an MPM-specific custom panel (MPM_geneset) comprising 1041 amplicons spanning 34 genes was performed. A total of 588 variants and 5309 mutational events were detected. In total, 91.3% of MPMs showed at least one mutation and 76.8% showed co-occurrence of more than one alteration. Mutations in MXRA5 ( = 0.05) and NOD2 ( = 0.018) were significantly associated with biph-MPM both in the training and validation cohort and correlated with the extent of the sarcomatoid component. Mutations in NOD2 and XRCC6 correlated with patients' survival. We demonstrated that biph-MPM are associated with a specific mutation set, and that genetic analysis at diagnosis may improve patients' risk stratification.
恶性胸膜间皮瘤(MPM)是一种异质性疾病。在形态学上,可区分出三种不同的表型:上皮样(e-)、肉瘤样(s-)和双相性(biph-)MPM,其中双相性MPM是e-MPM细胞和s-MPM细胞的混合物。作为一种中间实体,双相性MPM的治疗仍存在争议,不同的指南推荐了不同的方法。通过深度测序分析鉴定双相性MPM相关的基因改变,可能为理解这些病变提供有用的工具。我们选取了一个回顾性队列,包括69例手术切除的MPM,其中39例双相性MPM(56.5%)和30例上皮样MPM(43.5%)。另外一组16例双相性MPM用作验证集。对一个包含1041个扩增子、跨越34个基因的MPM特异性定制面板(MPM_基因集)进行深度测序分析。共检测到588个变异和5309个突变事件。总体而言,91.3%的MPM显示至少一个突变,76.8%显示存在一种以上改变的共现情况。在训练队列和验证队列中,MXRA5(P = 0.05)和NOD2(P = 0.018)的突变均与双相性MPM显著相关,且与肉瘤样成分的范围相关。NOD2和XRCC6的突变与患者的生存相关。我们证明双相性MPM与一组特定的突变相关,并且诊断时的基因分析可能改善患者的风险分层。